L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019
June 24, 2019 12:00 ET
|
Deinove
L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019 Le Major Steven Zumbrun (USAMRIID1, Département de la Défense des Etats-Unis) a présenté la...
DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019
June 24, 2019 12:00 ET
|
Deinove
DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019 Major Steven Zumbrun (USAMRIID1, U.S. Department of Defense) presented data on the in vitro assessment of...
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837
May 16, 2019 12:30 ET
|
Deinove
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837 Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic...
Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur to explore the potential of new targeted strains
April 09, 2019 12:30 ET
|
Deinove
Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur to explore the potential of new targeted strains The Institut Pasteur will provide a selection of strains for the DEINOVE...
DEINOVE passes the first milestone of the AGIR programm and receives €1.5m from Bpifrance
March 21, 2019 13:47 ET
|
Deinove
DEINOVE passes the first milestone of the AGIR programm and receives €1.5m from Bpifrance The robotic platform for extracting and screening antibiotic activities from bacterial strains is now...
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé
January 31, 2019 02:00 ET
|
Deinove
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer...
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
January 31, 2019 02:00 ET
|
Deinove
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in...